Physician profile
Rushmi Reehal
NPI 1780959742
$5,231.60
in general payments reported to CMS, 2019-2025
30 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $364 · 2023: $1,422 · 2024: $1,827 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.88 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.25 | 2022-2025 | |
| Ucb, INC. | $570.83 | 2023-2024 | Rystiggo, Briviact, Nayzilam |
| Genentech USA, INC. | $407.97 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Inspire Medical Systems, INC. | $399.12 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $373.75 | 2022-2025 | |
| Lilly USA, LLC | $250.24 | 2022-2025 | Kisunla, Zepbound, Amyvid |
| Sk Life Science, INC. | $245.94 | 2023-2025 | Xcopri |
| Neurelis, INC. | $241.69 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $235.49 | 2022-2025 | Ultomiris |
| Biogen, INC. | $225.98 | 2023-2025 | Vumerity, Tysabri |
| Idorsia Pharmaceuticals US INC | $219.97 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $217.67 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $114.09 | 2022-2025 | |
| Lundbeck LLC | $113.58 | 2023-2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $111.12 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $90.06 | 2023 | Wakix |
| Livanova USA, INC. | $84.96 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $77.79 | 2024-2025 | Vyvgart |
| Pfizer INC. | $76.82 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $74.23 | 2023-2024 | Aptiom |
| Avadel Cns Pharmaceuticals, LLC | $70.44 | 2024-2025 | Lumryz |
| Amneal Pharmaceuticals LLC | $55.42 | 2024 | Rytary |
| Genzyme Corporation | $49.39 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $39.13 | 2023-2024 | Amvuttra |
| Vanda Pharmaceuticals INC. | $30.98 | 2024 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $29.55 | 2024 | Austedo Xr |
| Grifols USA, LLC | $27.50 | 2024 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $25.19 | 2022 | |
| Tonix Medicines, INC. | $21.40 | 2025 | Zembrace Symtouch |
| Eisai INC. | $17.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushmi Reehal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.